Literature DB >> 7870983

Involvement of delta-opioid receptors in the effects of morphine on locomotor activity and the mesolimbic dopaminergic system in mice.

M Narita1, T Suzuki, M Funada, M Misawa, H Nagase.   

Abstract

Naltrindole (NTI) and naltriben (NTB), a benzofuran derivative of NTI, were recently synthesized as highly selective delta-opioid receptor antagonists. Both NTI and NTB failed to suppress the antinociceptive effect induced by morphine. In contrast, both NTI and NTB significantly suppressed the morphine-induced hyperlocomotion and increase in turnover of dopamine (DA) in the mouse limbic forebrain. These results suggest that delta-opioid receptors play, at least in part, a role in the morphine-induced hyperlocomotion and excitation of mesolimbic DA systems, but not antinociception.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7870983     DOI: 10.1007/bf02253531

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  16 in total

1.  Effects of intracerebroventricular beta-funaltrexamine on mu and delta opioid receptors in the rat: dichotomy between binding and antinociception.

Authors:  L Y Liu-Chen; S X Li; H Wheeler-Aceto; A Cowan
Journal:  Eur J Pharmacol       Date:  1991-10-15       Impact factor: 4.432

Review 2.  Anatomy of CNS opioid receptors.

Authors:  A Mansour; H Khachaturian; M E Lewis; H Akil; S J Watson
Journal:  Trends Neurosci       Date:  1988-07       Impact factor: 13.837

3.  Neuroanatomical boundaries of the reward-relevant opiate-receptor field in the ventral tegmental area as mapped by the conditioned place preference method in rats.

Authors:  M A Bozarth
Journal:  Brain Res       Date:  1987-06-23       Impact factor: 3.252

4.  Mu opioid receptor involvement in enkephalin activation of dopamine neurons in the ventral tegmental area.

Authors:  L G Latimer; P Duffy; P W Kalivas
Journal:  J Pharmacol Exp Ther       Date:  1987-04       Impact factor: 4.030

5.  beta-FNA binds irreversibly to the opiate receptor complex: in vivo and in vitro evidence.

Authors:  R B Rothman; J B Long; V Bykov; A E Jacobson; K C Rice; J W Holaday
Journal:  J Pharmacol Exp Ther       Date:  1988-11       Impact factor: 4.030

6.  Evaluation of delta receptor mediation of supraspinal opioid analgesia by in vivo protection against the beta-funaltrexamine antagonist effect.

Authors:  P Sánchez-Blázquez; J Garzón
Journal:  Eur J Pharmacol       Date:  1989-01-02       Impact factor: 4.432

7.  Pharmacological profiles of beta-funaltrexamine (beta-FNA) and beta-chlornaltrexamine (beta-CNA) on the mouse vas deferens preparation.

Authors:  S J Ward; P S Portoghese; A E Takemori
Journal:  Eur J Pharmacol       Date:  1982-06-04       Impact factor: 4.432

8.  Blockade of the morphine-induced increase in turnover of dopamine on the mesolimbic dopaminergic system by kappa-opioid receptor activation in mice.

Authors:  M Narita; T Suzuki; M Funada; M Misawa; H Nagase
Journal:  Life Sci       Date:  1993       Impact factor: 5.037

9.  Cocaine place preference is blocked by the delta-opioid receptor antagonist, naltrindole.

Authors:  K Menkens; E J Bilsky; K D Wild; P S Portoghese; L D Reid; F Porreca
Journal:  Eur J Pharmacol       Date:  1992-08-25       Impact factor: 4.432

10.  Opposite effects of mu and kappa opiate agonists on dopamine release in the nucleus accumbens and in the dorsal caudate of freely moving rats.

Authors:  G Di Chiara; A Imperato
Journal:  J Pharmacol Exp Ther       Date:  1988-03       Impact factor: 4.030

View more
  8 in total

1.  Newly Developed Dopamine D3 Receptor Antagonists, R-VK4-40 and R-VK4-116, Do Not Potentiate Cardiovascular Effects of Cocaine or Oxycodone in Rats.

Authors:  Chloe J Jordan; Bree A Humburg; Eric B Thorndike; Anver Basha Shaik; Zheng-Xiong Xi; Michael H Baumann; Amy Hauck Newman; Charles W Schindler
Journal:  J Pharmacol Exp Ther       Date:  2019-09-27       Impact factor: 4.030

2.  The effects of dopamine D1 and D2 receptor antagonists on the rewarding effects of delta 1 and delta 2 opioid receptor agonists in mice.

Authors:  T Suzuki; M Tsuji; T Mori; M Misawa; H Nagase
Journal:  Psychopharmacology (Berl)       Date:  1996-04       Impact factor: 4.530

3.  Augmentation of morphine-induced sensitization but reduction in morphine tolerance and reward in delta-opioid receptor knockout mice.

Authors:  V I Chefer; T S Shippenberg
Journal:  Neuropsychopharmacology       Date:  2008-08-13       Impact factor: 7.853

4.  Delta opioid receptors: reflexive, defensive and vocal affective responses in female rats.

Authors:  M Haney; K A Miczek
Journal:  Psychopharmacology (Berl)       Date:  1995-09       Impact factor: 4.530

5.  The effects of the kappa agonist U-50,488 on cocaine-induced conditioned and unconditioned behaviors and Fos immunoreactivity.

Authors:  C A Crawford; S A McDougall; C A Bolanos; S Hall; S P Berger
Journal:  Psychopharmacology (Berl)       Date:  1995-08       Impact factor: 4.530

6.  Effects of mu- and kappa-2 opioid receptor agonists on pain and rearing behaviors.

Authors:  John K Neubert; Heather L Rossi; Jonathan Pogar; Alan C Jenkins; Robert M Caudle
Journal:  Behav Brain Funct       Date:  2007-09-20       Impact factor: 3.759

7.  Voluntary movements as a possible non-reflexive pain assay.

Authors:  Hawon Cho; Yongwoo Jang; Byeongjun Lee; Hyeyoun Chun; Jooyoung Jung; Sung Min Kim; Sun Wook Hwang; Uhtaek Oh
Journal:  Mol Pain       Date:  2013-05-20       Impact factor: 3.395

Review 8.  Endogenous opiates: 1993.

Authors:  G A Olson; R D Olson; A J Kastin
Journal:  Peptides       Date:  1994       Impact factor: 3.750

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.